Genmab’s New Ofatumumab, Daratumumab Data Expected By Year End
This article was originally published in The Pink Sheet Daily
Executive Summary
Genmab has made progress with partnered lead antibodies ofatumumab and daratumumab in frontline CLL and refractory multiple myeloma respectively, while also boosting its financial guidance and cash balance.
You may also be interested in...
Janssen Boosts Multiple Myeloma R&D With Genmab Deal
Janssen Biotech has signed its second deal in less than two months with antibody discovery company Genmab, this time licensing the Danish company's potential first-in-class multiple myeloma therapy daratumumab for $55 million upfront and an equity investment.
Genmab's Star Falls Amid Setbacks, Cuts And Manufacturing Fire-Sale
What a difference a year makes. In October 2008, Genmab's leaders were being applauded for their prudent strategic review as they cut 101 staff and axed the development of Phase III HuMax-CD4 (zanulimumab) plus a handful of earlier-stage programs, to concentrate instead on the potentially far larger Arzerra (ofatumumab) and zalutumumab, a late-stage EGFR-inhibitor. But now management credibility is being questioned, following the Nov. 5 announcement of a further 300 headcount reduction, setbacks to both remaining key programs, plus the fire-sale of its U.S. manufacturing unit acquired only 18 months earlier
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.